| 09-18-2006 12:01 PM CET - Health & Medicine |
|
Researchers say Diclofenac may cause heart problems
Press release from: The Rasansky Law Firm
PR Agency: Page One
(openPR) - After over 30 years of use, researchers found that the pain medication Diclofenac causes heart problems. The new data indicates that people who suffer from high blood pressure or heart disease should avoid the drug.
In a new analysis of 23 studies, scientists found that the Diclofenac (also called "Cataflam" and "Voltaren") increased users' chance of heart attack by 40 percent.
The Journal of the American Medical Association released the study findings because of their important cardiac health implications. Sold for over 30 years, Diclofenac is a minor prescription drug in the United States but popular and easily obtained in other countries.
Researchers are firm about getting Diclofenac off the market. Even though the possibility that it will cause heart problems is low, its benefits are few when compared to other similar drugs. The FDA has responded to the diclofenac heart trouble findings, stating that the organization does not deem the new diclofenac data conclusive.
The study included an examination of 7 other pain drugs, including Naproxen (Aleve) and Celebrex. Both drugs fared better than diclofenac, which was the only one shown to pose a risk to cardiovascular health.
The report investigates the effects of a group of drugs called NSAIDs, nonsteroidal anti-inflammatory drugs.
The approximate number of people using NSAIDs is 30 million. Of those, very few suffer from heart problems.
Vioxx, belonging to a subset of NSAIDs called Cox-2 inhibitors, had to be removed from the market because it was found to cause heart problems similar to Diclofenac's. The Cox-2 inhibitors are supposedly easier on the stomach than some previously developed NSAID such as ibuprofen and naproxen.
The Cox-2 drugs did well commercially but Merck & Co. had to take Vioxx off the market when they learned that some patients were incurring heart problems.
The Rasansky Law Firm
2525 McKinnon Suite 625 Dallas, TX 75201
1-800-288-6763
www.texasinjuryattorney.com
At The Rasansky Law Firm, you will find experienced, aggressive Attorneys that are ready to provide the resources needed to win large, complex lawsuits. The Rasansky Law Firm continues to aggressively represent nationwide clients in cases involving, but not limited to: Absestos, Auto Accidents, Brain Injuries, Cerebral Palsy, Lasik, Medical Malpractice, Mesothelioma, Personal Injury, Paralysis, Nursing Home Abuse, Unpaid Overtime and Wrongful Death. The Rasansky Law Firm may be contacted at www.texasinjuryattorney.com
In a new analysis of 23 studies, scientists found that the Diclofenac (also called "Cataflam" and "Voltaren") increased users' chance of heart attack by 40 percent.
The Journal of the American Medical Association released the study findings because of their important cardiac health implications. Sold for over 30 years, Diclofenac is a minor prescription drug in the United States but popular and easily obtained in other countries.
Researchers are firm about getting Diclofenac off the market. Even though the possibility that it will cause heart problems is low, its benefits are few when compared to other similar drugs. The FDA has responded to the diclofenac heart trouble findings, stating that the organization does not deem the new diclofenac data conclusive.
The study included an examination of 7 other pain drugs, including Naproxen (Aleve) and Celebrex. Both drugs fared better than diclofenac, which was the only one shown to pose a risk to cardiovascular health.
The report investigates the effects of a group of drugs called NSAIDs, nonsteroidal anti-inflammatory drugs.
The approximate number of people using NSAIDs is 30 million. Of those, very few suffer from heart problems.
Vioxx, belonging to a subset of NSAIDs called Cox-2 inhibitors, had to be removed from the market because it was found to cause heart problems similar to Diclofenac's. The Cox-2 inhibitors are supposedly easier on the stomach than some previously developed NSAID such as ibuprofen and naproxen.
The Cox-2 drugs did well commercially but Merck & Co. had to take Vioxx off the market when they learned that some patients were incurring heart problems.
The Rasansky Law Firm
2525 McKinnon Suite 625 Dallas, TX 75201
1-800-288-6763
www.texasinjuryattorney.com
At The Rasansky Law Firm, you will find experienced, aggressive Attorneys that are ready to provide the resources needed to win large, complex lawsuits. The Rasansky Law Firm continues to aggressively represent nationwide clients in cases involving, but not limited to: Absestos, Auto Accidents, Brain Injuries, Cerebral Palsy, Lasik, Medical Malpractice, Mesothelioma, Personal Injury, Paralysis, Nursing Home Abuse, Unpaid Overtime and Wrongful Death. The Rasansky Law Firm may be contacted at www.texasinjuryattorney.com
News-ID: 11305
More releases
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
Please set a link in the press area of your homepage to this press release on openPR.
openPR disclaims liability for any content contained in this release.
© openPR 2012 | Imprint
More Releases from
The Rasansky Law Firm
Comments about openPR
OpenPR is clearly structured and remains true to its principle of confining itself to the essential parts.
OpenPR has proven to be a very good and reliable partner to our media agency:
Within the shortest time the releases are online and go down well with the media representatives.
The success of OpenPR is reflected in the steadily increasing number of press releases.
It is good that OpenPR exists!
Ursula Koslik,Director Marketing & PR, F+W Hamburg
OpenPR has proven to be a very good and reliable partner to our media agency:
Within the shortest time the releases are online and go down well with the media representatives.
The success of OpenPR is reflected in the steadily increasing number of press releases.
It is good that OpenPR exists!
Ursula Koslik,Director Marketing & PR, F+W Hamburg

